What is it about?
Pediatric coronavirus disease 2019 (COVID-19) and multisystem inflammatory syndrome in children (MIS-C) have been recognized in multiple countries globally. In this review, we provide recent insights into SARS-CoV-2 infection in children from epidemiological, clinical, and laboratory perspectives, including reports on the disease course and therapy. We highlight key features of SARS-CoV-2 infection in children, the relationship between MIS-C and Kawasaki disease, and summarize treatment guidelines for COVID-19 in children from institutional protocols from Colombia, case reports, recommendations based on expert consensus, and official statements from organizations such as the World Health Organization (WHO), United States Center for Disease Control (CDC), Colombian Association of Infectious Diseases, and the Colombian Society of Pediatrics. Finally, we discuss gaps in research with suggestions for future research on the pathogenesis underlying pediatric COVID-19.
Photo by National Cancer Institute on Unsplash
Why is it important?
While recent reports of pediatric infections show better prognosis than in adults, a growing number of children are being affected as transmission continues and the long-term impact in children is unknown. Furthermore, infections in children pose an important challenge for infection control measures. Therefore, it is justified to review the impact that SARS-CoV-2 has had on the pediatric population. This work aimed to review recent insights into SARS-CoV-2 infection in children from an epidemiological, clinical and laboratory perspective, including reports on the disease course and therapy.
Read the Original
This page is a summary of: Recent Insights into COVID-19 in Children and Clinical Recommendations, Current Pediatric Reviews, May 2022, Bentham Science Publishers, DOI: 10.2174/1573396317666211206124347.
You can read the full text:
The following have contributed to this page